NeuroOne Releases CNS Drug Delivery White Paper Ahead of Planned Fiscal Year-End Availability of the StereoCED(TM) Platform

EQS-News: NeuroOne Medical Technologies / Key word(s): Science NeuroOne Releases CNS Drug Delivery White Paper Ahead of Planned Fiscal Year-End Availability of the StereoCED(TM) Platform 30.07.2026 / 22:11 CET/CEST The issuer is solely responsible for the content of this announcement. White Paper Highlights How StereoCED is Designed to Address Key Barriers to the Scalable Commercial Delivery of Brain Therapeutics Through a Streamlined Robotic-Assisted Workflow

Device Availability for Research and Investigational Clinical Studies Expected by Fiscal Year-End

EDEN PRAIRIE, MINN. - July 30, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced the release of a new white paper titled “StereoCED - A Scalable Platform for CNS Drug Delivery”. The white paper can be downloaded from the Scientific Resources section of www.nmtc1.com or, click here.

The white paper highlights how advances in cell and gene therapies, biologics, and other central nervous system (CNS) therapeutics are increasing the demand for efficient, reproducible methods of delivering therapies directly to the brain. While convection-enhanced delivery (CED) has demonstrated the ability to bypass the blood-brain barrier and achieve targeted drug distribution, many current approaches may present challenges as therapies expand into broader commercial use.

The StereoCED drug delivery platform is being designed to address these challenges by leveraging robotic stereotactic systems already established in neurosurgical operating rooms. Rather than requiring specialized workflows and lengthy sequential infusions, the platform is being designed to support simultaneous, multi-trajectory intracranial drug delivery through a streamlined robotic workflow. This approach has the potential to significantly reduce procedure time while enabling reproducible, scalable therapeutic delivery. The StereoCED drug delivery platform is currently under development and has not been cleared or approved by the U.S. Food and Drug Administration for commercialization.

Schreibe Deinen Kommentar